Linagliptin and Newer DPP-4 Inhibitors: Newer Uses and Newer Indications
Sanjay Kalra, Ambika G. Unnikrishnan, Navneet Agrawal and Anupam K. Singh
Pages 197-202 (6)
The dipeptidyl peptidase-4 (DPP-4) inhibitors linagliptin, sitagliptin, saxagliptin, vildagliptin and alogliptin are being developed and have been approved for the treatment of type-2 diabetes. These agents may be used either as monotherapy for the treatment of type-2 diabetes or in combination with other anti-diabetic drugs. The present review highlights the use of linagliptin and other new (DPP-4) inhibitors in the management of type-2 diabetes. The review also highlights advantages, comparative pharmacokinetic, safety profile and other potential uses including potential newer indications of DPP-4 inhibitors and relevant patents. The other potential uses that are not restricted to diabetes include obesity, cardiovascular disease, neurological disease, hepatobiliary disease, wound healing, and other inflammatory illnesses.
Diabetes, Pharmacokinetics, placebo, DPP4 inhibitors, hepatic safety, incretins, linagliptin, oral hypoglycemics, multiple sclerosis, renal safety
Bharti Hospital, Kunjpura Road, Karnal, 132001, Haryana, India.